Search Results
Your search for The ASCO Post matches 17431 pages
Showing 15151 - 15200Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: ASCO/CCO Clinical Practice Guideline
The ASCO Clinical Practice Guidelines Committee and the Cancer Care Ontario (CCO) program in evidence-based care have released a clinical practice guideline on systemic therapy in men with metastatic castration-resistant prostate cancer. The guideline was published in the Journal of Clinical...
Sigmoidoscopy or Colonoscopy for Colorectal Cancer Screening: Is It Still the Question?
Mortality from colorectal cancer remains a public-health concern, being the second leading cause of cancer-related death for men and women combined. The major preventive measure for colorectal cancer is to screen for and remove adenomatous polyps. Average-risk individuals (ie, those who do not have ...
New Imaging Technique Identifies Receptors for Targeted Cancer Therapy
Dartmouth researchers have developed a fluorescence imaging technique that can more accurately identify receptors for targeted cancer therapies without a tissue biopsy. They report on their findings in a recently published article in Cancer Research.1 “Protein overexpression is a hallmark of...
The Harvard Global Equity Initiative: From Research to Policy
The Harvard Global Equity Initiative is a research program at Harvard University that is dedicated to promoting equitable global development, with a strong emphasis on health-care issues. This initiative brings together scholars, policymakers, advocates, and practitioners from around the world to...
FDA Grants Orphan Drug Designation to BGB324 for Acute Myeloid Leukemia
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BGB324 for the treatment of acute myeloid leukemia (AML). BGB324 is a first-in-class, highly selective small-molecule inhibitor of the Axl receptor tyrosine kinase. It blocks the epithelial-mesenchymal transition...
Power Behind ‘Master’ Gene for Cancer Discovered
A study at The University of Texas MD Anderson Cancer Center, Houston, led by Mong-Hong Lee, PhD, Professor of Molecular and Cellular Oncology, has demonstrated the significance of CSN6 in regulating Myc which may well open up a new pathway for treating and killing tumors. The study results are...
CAR T-Cell Therapy in Cancer: Driving Toward the Clinic
Chimeric antigen receptor (CAR) T-cell therapy represents a novel and promising therapeutic advance in cancer.1,2 It constitutes a form of personalized therapy that harnesses adoptive cell transfer through genetic engineering of autologous T cells. The initial step in this therapeutic paradigm...
Patients With Advanced Papillary Kidney Cancer Respond Well to Bevacizumab/Erlotinib Combination Therapy
Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anticancer drugs. The combination of bevacizumab (Avastin) and erlotinib (Tarceva) produced excellent...
Having Dependent Children Motivates Parents With Advanced Cancer to Pursue More Aggressive, Life-Extending Treatments
Findings from a pilot study of 42 parents with advanced cancer indicate that parental status is an important factor in treatment decision-making. When asked how having children influences their treatment decisions, the majority of parents (64%) responded that being a parent motivates them to pursue ...
Medicare Part D Low-Income Subsidy Program Improves Adherence to Hormone Therapy After Breast Cancer Surgery
Findings from a study of more than 23,000 women suggest that the Medicare Part D Extra Help program, which provides low-income subsidies for medications, improves adherence to hormone therapy after breast cancer surgery in all racial/ethnic groups and reduces racial/ethnic disparities. The study,...
ASH Pairs Hematologists From Developing and Developed Nations for Global Training Program
The American Society of Hematology (ASH) recently announced the 20 hematologists and other medical professionals selected to participate in the 2014 ASH Visitor Training Program. This program provides talented hematologists, scientists, and laboratory staff from developing countries the opportunity ...
FDA Approves Bevacizumab Plus Chemotherapy for Platinum-Resistant, Recurrent Ovarian Cancer
The U.S. Food and Drug Administration (FDA) approved bevacizumab (Avastin) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for the treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The approval is ...
2014 Featured Columnists
The ASCO Post wishes to acknowledge and thank all contributors to the publication during 2014. Here we recognize those who shared their personal thoughts in our Op-Ed department. If you are interested in contributing to The ASCO Post in 2015, write to editor@ASCOPost.com. Robert Peter Gale, MD,...
ASH Honors Senator Barbara Mikulski and Patient Advocate Kathy Giusti
The American Society of Hematology (ASH) recognized Senator Barbara Mikulski (D-MD) and Kathy Giusti, Founder of the Multiple Myeloma Research Foundation, with awards for their outstanding support and advocacy for biomedical research and the practice of hematology at the 56th ASH Annual Meeting in...
PD-L1 Expression by Tumor-Infiltrating Cells Associated With Activity of Anti–PD-L1 Antibody in Multiple Cancer Types
Programmed cell death protein ligand 1 (PD-L1) interferes with anticancer immune response by binding programmed PD-1 and B7.1 (CD80), negative regulators of T-cell activation. In a study reported in Nature, Herbst and colleagues showed that treatment with an anti–PD-L1 antibody (MPDL3280A) produced ...
Regis Chair for Breast Cancer Research Established
In partnership with the Regis Foundation for Breast Cancer Research, Regis Corporation, a leader in beauty salons and cosmetology, has announced that the Masonic Cancer Center at the University of Minnesota, Minneapolis, has established the Regis Chair for Breast Cancer Research. This milestone...
Appetite-Enhancing Agent Helps Patients Treated for NSCLC Gain Weight and Lean Body Mass and Feel Better
People have an image of stage III or IV lung cancer patients getting chemotherapy or chemoradiation, and they look terrible; they are losing weight. The fact is, when they respond, they can gain weight,” according to Philip Bonomi, MD, MS. He is the lead author of a phase III study showing that the ...
FDA Approves Ruxolitinib to Treat Patients With Polycythemia Vera
The U.S. Food and Drug Administration (FDA) approved a new use for ruxolitinib (Jakafi) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Ruxolitinib, a JAK inhibitor, is the first drug approved by the FDA for this condition. Polycythemia vera occurs when too many red ...
Additional Articles of Note
Adjuvant Bisphosphonates in Early Breast Cancer: Practice-Changing Findings January 15, 2014, Volume 5, Issue 1 Visit http://bit.ly/1rUM8CS HER2-Positive Breast Cancer Patients With Small Tumors Benefit From Low-Toxicity Regimen January 15, 2014, Volume 5, Issue 1 Visit http://bit.ly/1tA6UZ4...
Top 10 Articles From The ASCO Post in 2014
The following list presents those articles published in 2014 that were observed most often by visitors to ASCOPost.com, as measured by the number of views.a To view the full version of the articles listed below, visit ASCOPost.com and enter the URL provided below each entry. 1. Continuous...
2014 Oncology Meetings
JANUARY 2015 Melanoma 2015: 25th Annual Cutaneous Malignancy UpdateJanuary 10-11 • San Diego, California For more information: www.scripps.org/events/melanoma-annual-cutaneous-malignancy-update-january-10-2015 7th Breast Gynecological International Cancer ConferenceJanuary 15-16 • Cairo, Egypt For ...
Working Stiff: Two Years, 262 Bodies, and the Making of a Medical Examiner
Bookmark Title: Working Stiff: Two Years, 262 Bodies, and the Making of a Medical Examiner Authors: Judy Melinek, MD, and T.J. Mitchell Publisher: Scribner, a Division of Simon & Schuster, Inc Publication Date: August 2014 Price: $25.00; hardcover, 272 pages Just as the sun came up over a...
Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of necuparanib as a first-line treatment in combination with paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. Necuparanib is a novel oncology drug candidate engineered from...
FDA Approves Blinatumomab to Treat Rare Form of Acute Lymphoblastic Leukemia
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to blinatumomab (Blincyto) for the treatment of patients with Philadelphia chromosome–negative, relapsed or refractory precursor B-cell acute lymphoblastic leukemia (B-cell ALL). Blinatumomab is a bispecific...
ASH Releases Second List for Choosing Wisely Campaign
The American Society of Hematology (ASH) has announced five additional commonly used tests, treatments, and procedures in hematology that physicians and patients should question in certain circumstances. The additional items join an initial list of five practices to question that the Society...
Debate Over Legalizing Physician-Assisted Death for the Terminally Ill
On November 1, 2014, 29-year-old Brittany Maynard ended her life through physician-assisted death, reigniting the controversy surrounding Death With Dignity laws, which allow physicians to prescribe life-ending drugs to terminally ill patients. Diagnosed with glioblastoma multiforme in January, Ms. ...
AACR CEO Discusses the Global Status of Cancer at Seminar in Turin, Italy
Margaret Foti, PhD, MD (hc), Chief Executive Officer of the American Association for Cancer Research (AACR), recently spoke at the Institute for Cancer Research and Treatment (IRCC) in Turin, Italy, on November 25. Her lecture was titled “Reflections on the Global Cancer Research Landscape.” The...
Antacids Linked to Better Survival in Patients With Head and Neck Cancer
Patients with head and neck cancer who used antacid medicines to control acid reflux had better overall survival, according to a study from the University of Michigan Comprehensive Cancer Center. Results of the study were published in Cancer Prevention Research.1 Reflux can be a common side effect...
Karmanos Cancer Institute’s Hayley Thompson, PhD, Awarded $1.8 Million Grant to Improve Access to Cancer Survivor Resources
Hayley S. Thompson, PhD, Associate Professor, Population Studies and Disparities Research Program at the Barbara Ann Karmanos Cancer Institute, and Department of Oncology, Wayne State University School of Medicine, was recently awarded a $1.8 million grant from the Agency for Healthcare Research...
Dr. Matthew J. Ellis Named Director of Lester and Sue Smith Breast Center
Matthew J. Ellis, MD, PhD, a renowned clinician scientist in the area of genomics and molecular profiling of breast cancer, was named the new Director of the Lester and Sue Smith Breast Center at Baylor College of Medicine. Dr. Ellis assumed his new role in September 2014, succeeding C. Kent...
FDA Grants Breakthrough Therapy Designation to Investigational CAR T-Cell Therapy
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to JCAR015, an investigational chimeric antigen receptor therapy developed by Juno Therapeutics. The designation applies for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia and was...
Ixazomib Receives Breakthrough Therapy Designation for Relapsed or Refractory Systemic Light-Chain Amyloidosis
The U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy status to Takeda Pharmaceuticals’ investigational, oral proteasome inhibitor, ixazomib (MLN9708), for the treatment of relapsed or refractory systemic light-chain amyloidosis. This is the first proteasome inhibitor and...
Palliative Care in 2014
Palliative care expert Diane E. Meier, MD, is the Director of the Center to Advance Palliative Care (CAPC), a national organization devoted to enhancing the number and quality of palliative care programs across the nation. Under her leadership, the number of palliative care programs in the United...
RSNA Awards Gold Medal to Three Leaders in Radiology
The Radiological Society of North America (RSNA) awarded the Gold Medal, the organization’s highest honor, to three individuals at the RSNA 100th Scientific Assembly and Annual Meeting: Gary J. Becker, MD, of Tucson; Allen S. Lichter, MD, FASCO, of Alexandria, Virginia; and Etta D. Pisano, MD, of...
Cancer Care Incomplete Without Palliative Care Integration
ASCO recognizes that an array of efforts are needed to fully integrate palliative care into the cancer care continuum, and the Society is committed to facilitating the integration of palliative cancer care into existing health-care systems worldwide in order to realize the vision of comprehensive...
Immune-Suppressing Protein in Noncancerous Cells of Cancer Patients Offers Clue to Drug Response
A multicenter phase I study using an investigational immune therapy drug has found that the presence of the immune-suppressing protein PD-L1 in noncancerous immune cells can predict how patients with different types of advanced cancer will respond to treatment. The study, led by a Yale Cancer...
Benefits of Exercise for Relieving Fatigue in Cancer Survivors
Fatigue is such a common—and ongoing—problem among cancer survivors, last spring, ASCO published a clinical practice guideline1 to address screening, assessment, and treatment approaches for the management of fatigue after patients have completed treatment. Among the strategies included in the...
Racing Against Acute Lymphoblastic Leukemia: CTL019 Is a Fast CAR With Sustained Endurance
The long-term outcome for patients with relapsed or refractory acute lymphoblastic leukemia (ALL) is poor, with 5-year overall survival from first relapse being only approximately 10%.1,2 Patients with disease relapse following allogeneic transplant have the worse prognosis and are typically...
Getting the Most Out of Ipilimumab in Melanoma
Ipilimumab (Yervoy) was first approved by the U.S. Food and Drug Administration (FDA) in 2011 on the basis of an improvement in overall survival compared with gp100 vaccine in patients with advanced melanoma.1 Response rates with ipilimumab have been modest at best—10% to 15% using 3 mg/kg and 15%...
Moving a Mountain: Crizotinib in ROS1-Rearranged NSCLC
It was thousands of years ago in China. An elderly man was unhappy with the mountain that embraced his seaside village. He would need to walk for hours before he could reach the nearest town. So, as the old fable goes, he set his mind to move the mountain. Every day, he dug up basketfuls of rocks...
Marlo Thomas Receives Presidential Medal of Freedom
On November 24, 2014, St. Jude Children’s Research Hospital® National Outreach Director, Marlo Thomas, was presented with the Presidential Medal of Freedom, the nation’s highest civilian honor, during a special ceremony at the White House. With Ms. Thomas as its envoy to millions of supporters, St. ...
ASCO Expert Statement on Cancer Survivorship Care Planning: Timing Is Everything
As the saying goes, “Timing is everything.” And so it is with the recently released ASCO Clinical Expert Statement on survivorship care planning.1 Although there has been extensive discussion and debate about the use of survivorship care plans since the publication of the 2005 Institute of Medicine ...
Expert Point of View: Justin Gainor, MD
This is a very exciting time in lung cancer. Immunotherapy is extremely promising,” stated Justin Gainor, MD, a thoracic oncologist at Massachusetts General Hospital in Boston. The promise of immunotherapy extends to a broad patient population. Targeted treatments have transformed the lives of...
3D Mammography Improves Cancer Detection in Dense Breasts
A study presented at the annual meeting of the Radiological Society of North America (RSNA 2014) has found that digital breast tomosynthesis, also known as three-dimensional (3D) mammography, has the potential to significantly increase the cancer detection rate in mammography screening of women...
Breast Cancer Research Foundation Commits Record $58.6 Million in Research Grants
The Breast Cancer Research Foundation (BCRF) announced its dedication of $58.6 million to breast cancer research at its annual Symposium & Awards Luncheon. Totaling $47 million, the 2014–2015 annual grants, awarded to more than 220 physicians and scientists on six continents, continue to fuel...
Revisiting Successes in Advanced NSCLC to Test Value in Earlier-Stage Disease
Some pretty good evidence suggests that chemotherapy that works in advanced disease probably works even better in early-stage disease,” said Fadlo R. Khuri, MD, Chair, Department of Hematology and Medical Oncology at Winship Cancer Institute in Atlanta, in summarizing results from trials of...
CMS Issues Preliminary Decision to Cover Annual Lung Cancer Screening
In a long-awaited decision, the Centers for Medicare & Medicaid Services (CMS) has issued a preliminary proposal to cover annual lung cancer screening with low-dose computed tomography for appropriate beneficiaries following counseling and a shared–decision-making visit with a qualified...
ASCO Announces Major Steps in Development of CancerLinQ™
The American Society of Clinical Oncology (ASCO) announced that its wholly owned subsidiary, CancerLinQ LLC, will use the SAP HANA® platform in the development of ASCO’s CancerLinQ™. CancerLinQ is a groundbreaking health information technology platform that will harness Big Data to deliver...
Better Studies Needed to Dispel Confusion Over When to Refer a Patient to Hospice
I read the article on “Private Payer and Academic Center Data Capture Inappropriate Use of End-of Life Care” (The ASCO Post, December 15, 2014, page 11). The data highlight Dr. Deborah Schrag’s notion that there is “ample evidence of overuse of intensive care at the end of life.” However, there is...
Citing Guidelines May Reassure Patients
Whether deviations from treatment guidelines are warranted to provide optimal personalized care, or should be financially penalized for straying from evidence-based care, has raised questions among insurers and physicians and caused a stir in the press. In general, however, patients with cancer are ...
